Advertisement

Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause

  • Sania AmrEmail author
  • Beverly J. Wolpert
  • Diane Marie St. George
  • India James
  • Christopher A. Loffredo
Original Paper
  • 31 Downloads

Abstract

Purpose

Investigators have reported inconsistent findings regarding associations between body mass index (BMI) and bladder cancer risk, and they have postulated that sex steroids mediate such associations. We assessed the impact of BMI on the relationship between bladder cancer risk and combinations of age at first childbirth, parity, and age at menopause, among Egyptian women.

Methods

We used data from our multicenter case–control study of 419 cases and 786 controls in logistic regression models to estimate adjusted odds ratios (AORs) and 95% confidence intervals (CIs) of such associations.

Results

Age > 18 years at first childbirth and parity ≤ 6 were significantly associated with bladder cancer risk, which was higher when both factors (AOR = 2.31, 95% CI = 1.55–3.43) and age at menopause < 45 years (AOR = 3.51, 95% CI = 1.88–6.55) were present. Early menopause was associated with higher bladder cancer risk in obese (AOR = 2.90, 95% CI = 1.40–5.98) but not normal weight women (AOR = 0.98, 95% CI = 0.58–1.65; Pinteraction = 0.11), and the risk was greatest when both first childbirth at age > 18 years and parity ≤ 6 were present (AOR = 7.60, 95% CI = 1.84–31.35); however, overweight and obesity were associated with significantly lower bladder cancer risk (AOR = 0.59, 95% CI = 0.43–0.81, and AOR = 0.26, 95% CI = 0.18–0.38, respectively).

Conclusion

Body mass index appears to modify bladder cancer risk in Egyptian women after menopause by slightly enhancing the risk associated with low estrogen exposure among the obese only. Longitudinal studies of the BMI role in bladder malignancy in this distinctive population are required.

Keywords

Bladder cancer Body mass index Estrogen exposure Early menopause Egyptian women 

Notes

Acknowledgments

The authors thank Sameera Ezzat, Tamer El Hifnawy, and Doa’a Salah, who supervised the recruitment of subjects for this study. Iman Gouda, Iman Loay, and Bhaskar Kallakury performed the expert pathology review of the cases. Nabiel N. Mikhail provided data management services.

Funding

A grant from the National Cancer Institute, National Institutes of Health (R01-CA115618 to CAL), supported this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The institutional review boards of the 3 cancer referral centers (the National Cancer Institute in Cairo, the Oncology Center at Minia University, and the South Egypt Cancer Institute in Assiut), Egypt’s Ministry of Health, the University of Maryland, Baltimore, and Georgetown University approved the protocols.

Informed consent

Written informed consent was obtained from all participants.

References

  1. 1.
    Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96–108.  https://doi.org/10.1016/j.eururo.2016.06.010 CrossRefGoogle Scholar
  2. 2.
    Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558–568.  https://doi.org/10.1016/j.eururo.2016.06.010 CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang Y (2013) Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health Part C 31:287–304.  https://doi.org/10.1080/10590501.2013.844755 CrossRefGoogle Scholar
  4. 4.
    McGrath M, Michaud DS, De Vivo I (2006) Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 63:236–244.  https://doi.org/10.1093/aje/kwj028 CrossRefGoogle Scholar
  5. 5.
    Prizment AE, Anderson KE, Harlow BL, Folsom AR (2007) Reproductive risk factors for incident bladder cancer: Iowa Women’s Health Study. Int J Cancer 120:1093–1098.  https://doi.org/10.1002/ijc.22418 CrossRefPubMedGoogle Scholar
  6. 6.
    Wolpert BJ, Amr S, Ezzat S, Saleh DA, Gouda I, Loay I, Hifnawy T, Mikhail NN, Abdel-Hamid M, Zhan M, Zheng Y-L, Squibb K, Abdel-Aziz MA, Zaghloul M, Khaled H, Loffredo CA (2010) Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas 67:353–357.  https://doi.org/10.1016/j.maturitas.2010.07.014 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Daugherty SE, Lacey JV Jr, Pfeiffer RM, Park Y, Hoover RN, Silverman DT (2013) Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 133:462–472.  https://doi.org/10.1002/ijc.28022 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA (2016) Finasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol 69:407–410.  https://doi.org/10.1016/j.eururo.2015.08.029 CrossRefPubMedGoogle Scholar
  9. 9.
    Weibull CE, Eloranta S, Altman D, Johansson AL, Lambe M (2013) Childbearing and the risk of bladder cancer: a nationwide population-based cohort study. Eur Urol 63:733–738.  https://doi.org/10.1016/j.eururo.2013.01.005 CrossRefPubMedGoogle Scholar
  10. 10.
    Chiu HF, Chen BK, Yang C (2016) Parity, age at first birth, and risk of death from bladder cancer: a population-based cohort study in Taiwan. Int J Environ Res Public Health 13:E1197.  https://doi.org/10.3390/ijerph13121197 CrossRefPubMedGoogle Scholar
  11. 11.
    Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang YB, Gago-Dominguez M, Stern MC, Castelao JE, Conti DV, Pike MC, Bernstein L, Cortessis VK (2011) Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev 20:1156–1170.  https://doi.org/10.1158/1055-9965.EPI-11-0017 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Huang AT, Kogevinas M, Silverman DT, Malats N, Rothman N, Tardón A, Serra C, García-Closas R, Carrato A, Cantor KP (2009) Bladder cancer and reproductive factors among women in Spain. Cancer Causes Control 20:1907–1913.  https://doi.org/10.1007/s10552-009-9384-1 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    De Ridder J, Julián-Almárcegui C, Mullee A, Rinaldi S, Van Herck K, Vicente-Rodríguez G, Huybrechts I (2016) Comparison of anthropometric measurements of adiposity in relation to cancer risk: a systematic review of prospective studies. Cancer Causes Control 27:291–300.  https://doi.org/10.1007/s10552-015-0709-y CrossRefPubMedGoogle Scholar
  14. 14.
    Noguchi JL, Liss MA, Parsons JK (2015) Obesity, physical activity and bladder cancer. Curr Urol Rep 16:74.  https://doi.org/10.1007/s11934-015-0546-2 CrossRefPubMedGoogle Scholar
  15. 15.
    Qin Q, Xu X, Wang X, Zheng XY (2013) Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev 14:3117–3121.  https://doi.org/10.7314/APJCP.2013.14.5.3117 CrossRefPubMedGoogle Scholar
  16. 16.
    Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB (2015) Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS ONE 10:e0119313.  https://doi.org/10.1371/journal.pone.0119313 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Häggström C, Stocks T, Rapp K, Bjørge T, Lindkvist B, Concin H, Engeland A, Manjer J, Ulmer H, Selmer R, Tretli S, Hallmans G, Jonsson H, Stattin P (2011) Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 128:1890–1898.  https://doi.org/10.1002/ijc.25521 CrossRefPubMedGoogle Scholar
  18. 18.
    Cantiello F, Cicione A, Salonia A, Autorino R, De Nunzio C, Briganti A, Gandaglia G, Dell’Oglio P, Capogrosso P, Damiano R (2015) Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review. Int J Urol 22:22–32.  https://doi.org/10.1111/iju.12644 CrossRefPubMedGoogle Scholar
  19. 19.
    Renehan AG, Tuson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578.  https://doi.org/10.1016/S0140-6736(08)60269-X CrossRefPubMedGoogle Scholar
  20. 20.
    De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546.  https://doi.org/10.1155/2013/291546 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69:300–310.  https://doi.org/10.1016/j.eururo.2015.08.037 CrossRefPubMedGoogle Scholar
  22. 22.
    Zheng YL, Amr S, Saleh DA, Dash C, Ezzat S, Mikhail NN, Gouda I, Loay I, Hifnawy T, Abdel-Hamid M, Khaled H, Wolpert B, Abdel-Aziz MA, Loffredo CA (2012) Urinary bladder cancer risk factors in Egypt: a multicenter case–control study. Cancer Epidemiol Biomarkers Prev 21:537–546.  https://doi.org/10.1158/1055-9965.EPI-11-0589 CrossRefPubMedGoogle Scholar
  23. 23.
    Zhao L, Tian X, Duan X, Ye Y, Sun M, Huang J (2017) Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies. Oncotarget 8:33990–34000.  https://doi.org/10.18632/oncotarget.16722%5D CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556.  https://doi.org/10.1210/jc.2004-0395 CrossRefPubMedGoogle Scholar
  25. 25.
    Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, Kwon E, Leibovich B (2015) The estrogen pathway: estrogen receptor-α, progesterone receptor, and estrogen receptor-β expression in radical cystectomy urothelial cell carcinoma specimens. Clin Genitourin Cancer 13:476–484.  https://doi.org/10.1016/j.clgc.2015.04.001 CrossRefPubMedGoogle Scholar
  26. 26.
    Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109:1716–1726.  https://doi.org/10.1111/j.1464-410X.2011.10706.x CrossRefPubMedGoogle Scholar
  27. 27.
    Randolph JF Jr, Sowers MF, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ (2004) Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 89:1555–1561.  https://doi.org/10.1210/jc.2003-031183 CrossRefPubMedGoogle Scholar
  28. 28.
    Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD (2006) Estrogen—the good, the bad, and the unexpected. Endocr Rev 26:322–330.  https://doi.org/10.1210/er.2004-0020 CrossRefGoogle Scholar
  29. 29.
    Warner ET, Hu R, Collins LC, Beck AH, Schnitt S, Rosner B, Eliassen AH, Michels KB, Willett WC, Tamimi RM (2016) Height and body size in childhood, adolescence, and young adulthood and breast cancer risk according to molecular subtype in the Nurses’ Health Studies. Cancer Prev Res 9:732–738.  https://doi.org/10.1158/1940-6207.CAPR-16-0085 CrossRefGoogle Scholar
  30. 30.
    The Premenopausal Breast Cancer Collaborative Group (2018) Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol  https://doi.org/10.1001/jamaoncol.2018.1771 CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Epidemiology and Public HealthUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Marlene and Stuart Greenebaum Comprehensive Cancer CenterUniversity of Maryland School of MedicineBaltimoreUSA
  3. 3.U.S. Food and Drug Administration (FDA), Center for Food Safety and Applied NutritionCollege ParkUSA
  4. 4.Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashingtonUSA

Personalised recommendations